ATE307111T1 - Serinprotease-inhibitoren - Google Patents

Serinprotease-inhibitoren

Info

Publication number
ATE307111T1
ATE307111T1 AT00911572T AT00911572T ATE307111T1 AT E307111 T1 ATE307111 T1 AT E307111T1 AT 00911572 T AT00911572 T AT 00911572T AT 00911572 T AT00911572 T AT 00911572T AT E307111 T1 ATE307111 T1 AT E307111T1
Authority
AT
Austria
Prior art keywords
serine protease
protease inhibitors
compounds
factor
kallikrein
Prior art date
Application number
AT00911572T
Other languages
English (en)
Inventor
Ignacio Aliagas-Martin
Dean R Artis
Michael S Dina
John A Flygare
Richard A Goldsmith
Regina A Munroe
Alan G Olivero
Richard Pastor
Thomas E Rawson
Kirk D Robarge
Daniel P Sutherlin
Kenneth J Weese
Aihe Zhou
Yan Zhu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE307111T1 publication Critical patent/ATE307111T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00911572T 1999-01-13 2000-01-11 Serinprotease-inhibitoren ATE307111T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11577299P 1999-01-13 1999-01-13
US15202999P 1999-09-01 1999-09-01
PCT/US2000/000673 WO2000041531A2 (en) 1999-01-13 2000-01-11 Serine protease inhibitors

Publications (1)

Publication Number Publication Date
ATE307111T1 true ATE307111T1 (de) 2005-11-15

Family

ID=26813550

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00911572T ATE307111T1 (de) 1999-01-13 2000-01-11 Serinprotease-inhibitoren

Country Status (19)

Country Link
US (4) US6472393B1 (de)
EP (1) EP1144373B1 (de)
JP (1) JP2002534449A (de)
KR (1) KR100838418B1 (de)
CN (1) CN100488947C (de)
AT (1) ATE307111T1 (de)
AU (1) AU771776B2 (de)
BR (1) BR0008755A (de)
CA (1) CA2356934A1 (de)
CZ (1) CZ20012508A3 (de)
DE (1) DE60023266T2 (de)
ES (1) ES2251363T3 (de)
HU (1) HUP0105077A3 (de)
IL (2) IL144032A0 (de)
MX (1) MXPA01007038A (de)
NO (1) NO20013462L (de)
NZ (1) NZ512736A (de)
PL (1) PL350042A1 (de)
WO (1) WO2000041531A2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1144373B1 (de) * 1999-01-13 2005-10-19 Genentech, Inc. Serinprotease-inhibitoren
AU7447500A (en) * 1999-09-30 2001-04-30 Mitsubishi Chemical Corporation Acylsulfonamide derivatives
CA2426430C (en) 2000-10-20 2014-10-07 Biocryst Pharmaceuticals, Inc. Biaryl compounds as serine protease inhibitors
JP4179878B2 (ja) * 2001-02-02 2008-11-12 中外製薬株式会社 ペプチド誘導体
DE10130374A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Substituierte N-Acyl-anilinderivate, deren Herstellung und deren Verwendung als Arzneimittel
AU2003219039A1 (en) * 2002-03-11 2003-09-22 Curacyte Ag Urokinase inhibitors, production and use thereof
GB0207637D0 (en) * 2002-04-02 2002-05-15 Karobio Ab Novel compound
AU2003231865A1 (en) * 2002-05-31 2003-12-19 Genzyme Corporation Alpha acyloxyacetamides for kallikrein and urokinase inhibition
DE10301300B4 (de) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US7144895B2 (en) * 2003-02-11 2006-12-05 Bristol-Myers Squibb Co. Benzene acetamide compounds useful as serine protease inhibitors
EP1594505A4 (de) * 2003-02-11 2008-08-13 Bristol Myers Squibb Co Phenylglycin-derivate als serin-protease-hemmer
CA2525713A1 (en) * 2003-05-20 2004-12-29 Genentech, Inc. Benzofuran inhibitors of factor viia
WO2004113278A2 (en) * 2003-05-20 2004-12-29 Genentech, Inc. Acylsulfamide inhibitors of factor viia
DE10342108A1 (de) * 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
DE602006016566D1 (de) * 2005-01-10 2010-10-14 Bristol Myers Squibb Co Als antikoagulanzien verwendbare phenylglycinamid-derivate
WO2006104945A2 (en) 2005-03-29 2006-10-05 Biocryst Pharmaceuticals, Inc. Hepatitis c therapies
US8101636B2 (en) * 2005-06-03 2012-01-24 The University Of North Carolina At Chapel Hill Linear dicationic terphenyls and their aza analogues as antiparasitic agents
US7964619B2 (en) * 2005-06-03 2011-06-21 The University Of North Carolina At Chapel Hill Teraryl components as antiparasitic agents
US7456195B2 (en) * 2005-06-24 2008-11-25 Bristol-Myers Squibb Company Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
NZ571441A (en) * 2006-03-24 2010-08-27 Eisai R&D Man Co Ltd Triazolone derivative
US7776832B2 (en) 2006-04-21 2010-08-17 Gem Pharmaceuticals, Llc Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
TW200831080A (en) * 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MX2009007333A (es) 2007-01-12 2009-08-31 Biocryst Pharm Inc Analogos de nucleosidos antivirales.
CA2683316A1 (en) 2007-04-13 2009-02-19 Southern Research Institute Anti-angiogenic agents and methods of use
JP2010535240A (ja) * 2007-07-31 2010-11-18 マリンクロッド・インコーポレイテッド 一体化光活性薬剤およびその使用
JPWO2009038157A1 (ja) 2007-09-21 2011-01-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ２，３−ジヒドロ−イミノイソインドール誘導体
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
AU2010222537B2 (en) 2009-03-10 2016-06-30 Med Discovery Sa Use of serine protease inhibitors in the treatment of neutropenia
TW201206905A (en) 2010-05-20 2012-02-16 Eisai R & Amp D Man Co Ltd Prodrug of triazolone compound
WO2012004678A2 (en) 2010-07-07 2012-01-12 The Medicines Company (Leipzig) Gmbh Serine protease inhibitors
WO2013166276A1 (en) 2012-05-02 2013-11-07 Southern Research Institute Triazolopyridazine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof
ES2919024T3 (es) 2014-02-11 2022-07-21 Mitokinin Inc Composiciones y procedimientos que utilizan las mismas para el tratamiento de enfermedades neurodegenerativas y mitocondriales
JP2018537502A (ja) 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
EP3541391A4 (de) 2016-11-17 2020-06-17 The University of North Carolina at Chapel Hill Alkyl-pyrrolopyrimidin-analoga und verfahren zur herstellung und verwendung davon
US10450263B2 (en) 2017-02-10 2019-10-22 Southern Research Institute Benzo annulenes as antiviral agents
US11160826B1 (en) 2017-03-03 2021-11-02 United States Government As Represented By The Department Of Veterans Affairs Cholesterol lowering drugs for the treatment of hepatic encephalopathy
AU2018290225A1 (en) 2017-06-21 2020-01-23 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
WO2019084455A1 (en) 2017-10-26 2019-05-02 Southern Research Institute DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS
WO2019089693A1 (en) 2017-10-31 2019-05-09 Southern Research Institute Substituted quinazoline sulfonamides as thioredoxin interacting protein (txnip) inhibitors
TWI873092B (zh) 2018-04-06 2025-02-21 美商百歐克斯製藥公司 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑
WO2019204637A1 (en) 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
CN113365614A (zh) 2018-10-02 2021-09-07 由退伍军人事务部代表的美国政府 作为神经保护剂的spak激酶抑制剂
US20220251134A1 (en) 2019-06-14 2022-08-11 Southern Research Institute 2,4,7-substituted-7-deaza-2'-deoxy-2'-fluoroarabinosyl nucleoside and nucleotide pro-drugs and uses thereof
BR112022004910A2 (pt) 2019-09-17 2022-06-07 Univ Utah Res Found Benzimidazóis e métodos de uso dos mesmos
AR120173A1 (es) 2019-10-09 2022-02-02 Biocryst Pharm Inc Inhibidores del factor d del complemento para administración oral
CA3159698A1 (en) 2019-12-04 2021-06-10 Southern Research Institute Modulators of programmed death-ligand-1 and/or programmed death-ligand-2
CN115916175A (zh) 2020-04-02 2023-04-04 南方研究院 作为针对甲病毒属的有效抗病毒剂的新型2-嘧啶酮类似物
AR121715A1 (es) 2020-04-03 2022-06-29 Biocryst Pharm Inc Pirrolopirimidinaminas como inhibidores del sistema del complemento
WO2021222637A1 (en) 2020-04-30 2021-11-04 United States Government As Represented By The Department Of Veterans Affairs Krüppel-like factor 15 (klf15) small molecule agonists in kidney disease
JP2023545015A (ja) 2020-10-02 2023-10-26 ミトキニン インコーポレイテッド 腎疾患及び線維症を治療する組成物及び方法
WO2022109066A1 (en) 2020-11-18 2022-05-27 Southern Research Institute Compounds for the treatment of acute and chronic kidney disease
EP4247375A4 (de) 2020-11-18 2024-11-20 Southern Research Institute Verbindungen zur behandlung von akuter und chronischer nierenerkrankung
EP4422643A4 (de) 2021-10-26 2025-11-26 Southern Res Inst Entwicklung neuartiger clofarabin-analoga zur krebstherapie
WO2023122212A2 (en) 2021-12-21 2023-06-29 Southern Research Institute Substituted phenyl ethynyl pyridine carboxamides as potent inhibitors of sars virus
US20250108066A1 (en) 2022-01-27 2025-04-03 Trilink Biotechnologies, Llc Trinucleotide cap analogs and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
DE4342154A1 (de) * 1993-12-10 1995-06-14 Behringwerke Ag Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien
ES2193202T3 (es) 1994-12-02 2003-11-01 Yamanouchi Pharma Co Ltd Nuevo derivado de amidinonaftilo o sal de este.
DE69630214T2 (de) * 1995-03-10 2004-07-15 Berlex Laboratories, Inc., Richmond Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
JP2000514788A (ja) * 1996-06-25 2000-11-07 イーライ・リリー・アンド・カンパニー 抗凝固剤
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
TW542822B (en) * 1997-01-17 2003-07-21 Ajinomoto Kk Benzamidine derivatives
NZ500354A (en) 1997-04-14 2001-11-30 Cor Therapeutics Inc Cyclic diaza compounds as selective factor Xa inhibitors for treating thrombotic related disorders
WO1998046628A1 (en) * 1997-04-14 1998-10-22 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
US6369063B1 (en) * 1997-04-14 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
AU6896298A (en) * 1997-04-14 1998-11-11 Cor Therapeutics, Inc. Selective factor xa inhibitors
DE19718181A1 (de) 1997-04-30 1998-11-05 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
EP0987274A1 (de) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Faktor VIIa Inhibitore
EP1144373B1 (de) * 1999-01-13 2005-10-19 Genentech, Inc. Serinprotease-inhibitoren

Also Published As

Publication number Publication date
US20070037813A1 (en) 2007-02-15
HUP0105077A2 (hu) 2002-05-29
CA2356934A1 (en) 2000-07-20
DE60023266D1 (de) 2005-11-24
NZ512736A (en) 2003-11-28
DE60023266T2 (de) 2006-07-13
CN100488947C (zh) 2009-05-20
NO20013462D0 (no) 2001-07-12
AU3345100A (en) 2000-08-01
CN1342139A (zh) 2002-03-27
ES2251363T3 (es) 2006-05-01
EP1144373A3 (de) 2002-01-02
PL350042A1 (en) 2002-10-21
WO2000041531A3 (en) 2001-08-16
US20050186198A1 (en) 2005-08-25
US6919369B2 (en) 2005-07-19
MXPA01007038A (es) 2002-07-30
KR100838418B1 (ko) 2008-06-13
NO20013462L (no) 2001-09-12
WO2000041531A2 (en) 2000-07-20
KR20010101852A (ko) 2001-11-15
IL144032A0 (en) 2002-04-21
CZ20012508A3 (cs) 2002-02-13
AU771776B2 (en) 2004-04-01
EP1144373B1 (de) 2005-10-19
JP2002534449A (ja) 2002-10-15
HUP0105077A3 (en) 2005-04-28
US20030212071A1 (en) 2003-11-13
IL144032A (en) 2006-06-11
US6472393B1 (en) 2002-10-29
BR0008755A (pt) 2007-05-29
EP1144373A2 (de) 2001-10-17

Similar Documents

Publication Publication Date Title
ATE307111T1 (de) Serinprotease-inhibitoren
MXPA03009130A (es) Compuestos de biarilo que funcionan como inhibidores de proteasa serina.
ATE438615T1 (de) Biarylverbindungen als serinproteaseinhibitoren
ATE268766T1 (de) Stickstoff enthaltende heterobicyclen als factor xa inhibitoren
AP2004003035A0 (en) Inhibitors of factor xa and other serine proteasesinvolved in the coagulation cascade.
WO2002000651A3 (en) Factor xa inhibitors
DE60122750D1 (de) Amidine-inhibitoren der serine-proteasen
TR200103493T2 (tr) Metaloproteaz önleyicileri
NO20015462L (no) Anvendelse av fthalazinderivater
MXPA02011411A (es) Inhibidores de proteasa de serina.
TR199801569T2 (xx) Serin proteaz inhibit�rleri.
PL319782A1 (en) Inhibitors of serinic proteases and anticoagulative protecins extracted from nematodes
WO2004113278A3 (en) Acylsulfamide inhibitors of factor viia
DE60113412D1 (de) Inhibitoren von serin proteasen
NO20004698L (no) Quinoksalinoner som serin protease inhibitorer sÕ som faktor XA og trombin
TR199801704T2 (xx) Serin proteaz inhibit�rleri.
NO20002848L (no) Nye forbindelser
ATE303989T1 (de) Inhibitoren von serin proteasen
WO2002002519A3 (en) THROMBIN OR FACTOR Xa INHIBITORS
NO20010569L (no) Proteaseinhibitorer for anvendelse ved behandling av psoriasis
IL160068A0 (en) Mew mandelic acid derivatives and their use as thrombin inhibitors
DE69732784D1 (de) Inhibierung von invasiver remodulierung
BG105985A (en) Prodrugs of thrombin inhibitors
WO2003051831A3 (en) Protease inhibitors of the coagulation cascade isolated from dysidea sponges

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties